Podcasts about mgus

What does it take to fundamentally rethink how specialty insurance is traded, structured and scaled? In this episode, Robin Merttens is joined by Jeff Radke, co-founder and CEO of Accelerant, for a deep dive into the mechanics of a rapidly growing risk exchange that's quietly reshaping the MGA and MGU landscape. It has been three years since Jeff joined us on the InsTech podcast, and even Accelerant has radically evolved as a business. This isn't, however, just another technology story. Jeff shares frank insights on building trust in a data-driven ecosystem, how Accelerant has used AI to make tangible portfolio improvements and why he believes platform-based risk trading will become the dominant model for specialty lines. Unlike many other discussions about AI in insurance, this episode focuses on what's already working – from subrogation improvements to portfolio optimisation. There's also a broader message here: about stepping back to see how much the market has changed and why the next evolution may already be underway… Key Talking Points Building a global risk exchange – how Accelerant connects specialty MGAs and MGUs with capacity through a single, scalable platform The value of long-term partnerships – why Accelerant provides five-year capacity commitments and expects transparency in return From niche to global – supporting 200+ underwriting teams across 20 countries and over 225 specialty products Applying AI where it matters – reducing loss ratios and boosting subrogation with machine learning and large language models Cost leadership in a softening market – why expense ratio advantage trumps rate cycles in SME and specialty risks Looking ahead – how AI is reshaping roles, workflows and the entire insurance value chain The rise of risk exchanges – why specialty insurance is following the same path as bonds, mortgages and equities Staying ahead – why Accelerant is focused on evolution, not just competition If you like what you're hearing, please leave us a review on whichever platform you use or contact Robin Merttens on LinkedIn. You can also contact Jeff Radke on LinkedIn to start a conversation! Sign up to the InsTech newsletter for a fresh view on the world every Wednesday morning. Continuing Professional Development This InsTech Podcast Episode is accredited by the Chartered Insurance Institute (CII). By listening, you can claim up to 0.5 hours towards your CPD scheme. By the end of this podcast, you should be able to meet the following Learning Objectives: Describe how a modern risk exchange connects specialty underwriters with capital providers. Identify the signs of systemic evolution in the insurance industry that indicate a shift toward platform-based models. Define the concept of a two-sided risk exchange and its advantages over traditional capacity models. If your organisation is a member of InsTech and you would like to receive a quarterly summary of the CPD hours you have earned, visit the Episode 348 page of the InsTech website or email cpd@instech.co to let us know you have listened to this podcast. To help us measure the impact of the learning, we would be grateful if you would take a minute to complete a quick feedback survey.

On this episode Lara and Vyanka talk to Prof Guy Pratt from The University of Birmingham all about the diagnosis of, management of and advances in plasma cell disorders like MGUS and multiple myeloma. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

Episode 184: Multiple Myeloma BasicsSub-Interns and future Drs. Di Tran and Jessica Avila explain the symptoms, work up and treatment of multiple myeloma. Written by Di Tran, MSIV, Ross University School of Medicine; Xiyuan Yang, MSIV, American University of the Caribbean. Comments by Jessica Avila, MSIV, American University of the Caribbean. Edits by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Di: Hi everyone, this is Di Tran, 4th year medical student from Ross university.  It's a pleasure to be back.  To be honest, this project is a part of teamwork of two medical students, myself and another 4th year, her name is XiYuan.  She came from the AUC. Unfortunately, due to personal matters she was unable to make it to the recording today which makes me feel really sad. Jessica: My name is Jessica Avila, MSIV, American University of the Caribbean.Di: The topic we will present today is Multiple Myeloma. Multiple myeloma is typically a rare disease and it's actually a type of blood cancer that affects plasma cells in the bone marrow.Jessica: Let's start with a case: A 66-year-old male comes to his family doctor for an annual health checkup. He is not in any acute distress but he reports that he has been feeling tired and weaker than usual for the last 3 months. He also noticed that he tends to bruise easily. He has a history of arthritis and chronic joint pain, but he thinks his back pain has gotten worse in the last couple of months. Upon checking his lab values, his family doctor found that he has a calcium level of 10.8 and a creatinine level of 1.2, which has increased from his baseline. Given all that information, what do you think his family doctor is suspecting? And what kind of tests she can order for further evaluation?Di: Those symptoms sound awfully familiar – are we talking about the CRAB? You know, the diagnostic criteria for Multiple Myeloma.Jessica: Exactly! Those are called “myeloma-defining events.” Do you remember what those are?Di: CRAB criteria comes in 4 flavors.  It's HYPERCALCEMIA with >1mg/dL, RENAL INSUFFICIENCY with serum creatinine >2mg/dL, ANEMIA with hemoglobin value 10% plasma cells, PLUS any one or more of the CRAB features, we can make the official diagnosis of multiple myeloma. Di:  Before we go deeper, let's back up a little bit and do a little background.  So, what do we know about the immunoglobulins, also known as antibodies? Back from years of studying from medical school, we know that the plasma cells are the ones that producing the antibodies that help fight infections.  There  are various kinds that come with various functions.  Each antibody is made up of 2 heavy chains and 2 light chains.  For heavy chains, we have A, D, E, G, M and for light chains we have Kappa and Lambda.Jessica: Usually, the 5 possible types of immunoglobulins for heavy chains would be written as IgG, IgA, IgD, IgE, and IgM.  And the most common type in the bloodstream is nonetheless the IgG. Di: What is multiple myeloma? In myeloma, all the abnormal plasma cells make the same type of antibody, the monoclonal antibody.  The cause of myeloma is unknown, but there are lots of studies and evidence that show a number of potential etiologies, including viral, genetic, and exposure to toxic chemicals, especially the Agent Orange, which is a chemical used as herbicide and defoliant. It was used as a chemical warfare by the U.S. military during the Vietnam War from 1961 to 1971.Jessica: We need to order some specific blood tests to see if there is elevated monoclonal proteins in the blood or urine. So, to begin with we'll need to take a very thorough history and physical exam. Next, we'll do labs, such as CBC, basic metabolic panel, calcium, serum beta-2 microglobulin, LDH, total protein, and some not so common tests: serum protein electrophoresis (SPEP), immunofixation of blood or urine (IFE), quantitative immunoglobulins (QIg), serum free light chain assay, and serum heavy/light chain ratio assay.If any of the results is abnormal, we should consider referring our patient to an oncologist.Di: Interesting! I read that Multiple Myeloma symptoms vary in different patients.  In fact, about 10-20% of patients with newly diagnosed myeloma do not have any symptoms at all.   Otherwise, classic symptomatic presentations are weakness, fatigue, increased bruising under the skin, reduced urine output, weakened bones that is likely prone to fractures, etc. And if multiple myeloma is highly suspected, a Bone Marrow biopsy should be done with testing for flow cytometry and fluorescent in situ hybridization (FISH). Actually, if any of the “Biomarkers of malignancy (SLIM)” is met we can also diagnose multiple myeloma even without the CRAB criteria. Jessica: The diagnosis is made if one or more of the following is found: >= 60% of clonal plasma cells on bone marrow biopsy, > 1 lytic bone lesion on MRI that is at least 5mm in size, or a biopsy confirmed plasmacytoma. Di: Imaging comes in at the final step especially if we able to find one or more sites of osteolytic bone destruction > 5mm on an MRI scan.Jessica: What if the bone marrow biopsy returns > 10% of monoclonal plasma cells, but our patient doesn't have either the CRAB or the Biomarker criteria? Di: That's actually a very good question, since Multiple Myeloma is part of a spectrum of plasma cell disorders. That's when smoldering myeloma comes into play. It is a precursor of active multiple myeloma. Smoldering myeloma is further categorized as high-risk or low-risk based on specific criteria.A less severe form is called Monoclonal Gammopathy of Undetermined Significance, or simply MGUS, with < 10% bone marrow involvement. Those are diagnoses we give once we rule out actual multiple myeloma, which are defined by the amount of M-protein in the serum.Jessica:  When to get started on treatment? Multiple Myeloma is on a spectrum of plasma cells proliferative disorders, starting from MGUS to Smoldering Myeloma, to Multiple Myeloma and to  Plasma Cell Leukemia.  Close supervision/active watching is enough for MGUS and low risk Smoldering Myeloma. But once it has progressed to high-risk smoldering myeloma or to active Multiple Myeloma, chemotherapy is usually required. Some situations may require emergent treatment to improve renal function, reduce hypercalcemia, and to prevent potential infections.Di: As of 2024, treatment of Multiple Myeloma comprises the Standard-of-Care approved by the FDA. In fact, the quadruple therapy is a combination of 4 different class of drugs that include a monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug, and a steroid. Jessica: They are Darzalex (daratumumab), Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone.  Other treatment plans for Multiple Myeloma include chemotherapy, immunotherapy, radiation therapy (for plasmacytomas) and stem cell transplants. The patient will also be on prophylaxis acyclovir and Bactrim while on chemotherapy. Sometimes anticoagulants are also considered because the chemo increases the risk of venous thromboembolic events.Di: Although the disease is incurable, but with the advancing of novel therapies and clinical trials patients with multiple myeloma are able to live longer.  Problem is the majority of patients diagnosed with Multiple Myeloma are older adults (>65), the risk of falling is adding to multiple complications of the disease itself, such as bone density loss, pain, neurological compromises, distress and weakness.  Palliative care may come in help at any point in time throughout the course of treatment but is most often needed at the very end of the course. Jessica, can you give us a conclusion for this episode?Jessica: Multiple Myeloma may not be the most common cancer, but we have to be aware of the symptoms and keep it in our differential diagnosis for patients with bone pain, easy bruising, persistent severe headaches, unexplained renal dysfunction, and remember the CRAB: HyperCalcemia, Renal impairment, Anemia and Bone lesions.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:International Myeloma Foundation. (n.d.). International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. https://www.myeloma.org/international-myeloma-working-group-imwg-criteria-diagnosis-multiple-myeloma Laubach, J. P. (2024, August 28). Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics). UpToDate. https://www.uptodate.com/contents/multiple-myeloma-symptoms-diagnosis-and-staging-beyond-the-basics.University of California San Francisco. (n.d.). About multiple myeloma. UCSF Helen Diller Family Comprehensive Cancer Center. https://cancer.ucsf.edu/research/multiple-myeloma/about Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Dawn Walker is an associate director, Industry Relations (DUAE) in AM Best's Strategy and Communications department. Dawn has more than 15 years of insurance industry and risk management experience, and joined AM Best in 2022, initially serving as a senior financial analyst, conducting performance assessments for Delegated Underwriting Authority Enterprises.  Previously, Dawn as a senior risk management analyst at MacAndrews & Forbes Inc., a global mergers and acquisitions firm in New York City. She also previously served as a senior account executive for Alliant Insurance Services, serving its ultra-high net worth book of business.  Dawn received her MBA degree with a concentration in Enterprise Risk Management at St. John's University. She graduated Cum Laude earning a Bachelor of Law degree from the University of Arizona. She holds a Property & Casualty and Life & Health Broker's license, has earned an Associate in Risk management (ARM) designation and is actively pursuing a Charter Property Casualty Underwriter's designation. Highlights from the Show AM Best is known for many things, but mainly for the assessments and ratings they perform on players across the insurance industry. For the Delegated Underwriting Authority Enterprise (DUAE) space in particular, they are bringing transparency to help drive continued growth not only of the DUAE segment, but the product innovation that goes on within it. The level of growth in the delegated underwriting authority space has been huge, getting to $77B in the US alone, and making up 10% of the P&C market globally. The key areas they look at when assessing DUAEs includes Operations, UW Capabilities, Governance and Controls, Financials and Corporate Structure. This analysis helps bring transparency to the sector to help facilitate partnerships while also giving DUAEs a blueprint for how to optimize their operations for growth, stability and, ultimately, success Why do insurers work with Delegated Underwriting Authority Enterprises (DUAEs), like MGAs and MGUs? Can't they just compete in the market directly? DUAEs bring expertise in niches and market segments that incumbent carriers may not be able to build efficiently given their scale, and the relative size of these niches being too small to support the operational cost of a carrier. DUAEs often come with expertise and distribution in the segment, allowing carriers working with them to access new spaces efficiently, quickly and profitably. What can support or stand in the way of the success of a Delegated Underwriting Authority Enterprises (DUAEs), like MGAs and MGUs? AM Best performs assessments of these entities to bring transparency to key success factors insurers would look at when deciding whether to work with a DUAE or not. This episode is brought to you by The Future of Insurance thought leadership series, available globally from Amazon in print, Kindle and Audible audiobook. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O'Donnell, Director of Early Detection and Prevention at Dana-Farber.

In episode 12, we're joined by haematology consultant Dr Suzanne Roberts to discuss myeloma. Dr Roberts explains what kind of pain to look out for – like back pain – in this type of blood cancer and how to tell the difference between a musculoskeletal pain versus a pain without a mechanism of injury, or a new-onset pain. She talks through other symptoms like fatigue and anaemia, the C.R.A.B acronym, MGUS, staging ,and the primary care investigations she would recommend. You can access the guidelines and studies referenced here. Accessibility: Access the full episode transcript here. If you loved this episode and would like to hear more like this, please leave a review, a rating and share the episode. GPs Talk Cancer is the podcast series from GatewayC. GatewayC is the free early cancer diagnosis resource funded by the NHS and is part of The Christie NHS Foundation Trust. Produced by Louise Harbord from GatewayC, and Jo Newsholme from Rethink Audio.DISCLAIMER: We know this podcast might be of interest to anybody, however it is aimed at primary care health professionals. All patient cases are based on real stories from our clinical practice as GPs. They are fully anonymised with no identifiable patient data. All featured statistics are accurate at the time of recording. All views expressed by guest speakers are their own. Hosted on Acast. See acast.com/privacy for more information.

Tony chats with Jeff Radke, Co-Founder and CEO at Accelerant Holdings. Accelerant has been around for 5 years and exists to improve the specialty insurance value chain. They are "replatforming" the specialty insurance market. They serve specialty underwriters (MGAs and MGUs) and on the other side they serve risk capital sources. Their vision is an incredibly efficient infrastructure that reduces friction as much as possible.Jeff Radke: https://www.linkedin.com/in/jeff-radke/Accelerant: https://accelerant.ai/Video Version: https://youtu.be/OT_Lzaq1tIgWhat It's Like To Be...What's it like to be a Cattle Rancher? FBI Special Agent? Professional Santa? Find out!Listen on: Apple Podcasts Spotify

Tune into this week's epsiode of of The Leadrship In Insurance Podcast : A Deep Dive Into MGUs, Digital Underwriting & MGA Opportunites with Caroline Taylor ACII, COO at ACIES MGU➡ Why do we need another MGU platform?➡ What do you mean when you say digital underwriting? Is this not just how underwriting is done?➡ You have some pledges around social and environmental issues - what are you doing practically?➡ Acies has significant growth ambitions over the next few years to support a growing number of MGAs - its a competitive landscape how do you secure the best MGA opportunities? Hosted on Acast. See acast.com/privacy for more information.

Is there anything you can suggest to people with MGUS to proactively keep multiple myeloma at bay?; Would you please comment on the recent study that showed no benefits to time-restricted eating?; Our 12-year-old grandson has Sever's disease. Any supplements you would recommend for him?

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Monoclonal Gammopathy of Undetermined Significance (MGUS)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the... The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.

Unlock the secrets behind the burgeoning InsurTech industry with David Gritz, the co-founder and managing director of InsurTechNY. ✅ Join over 5,000 newsletter subscribers: https://go.ryanhanley.com/** ✅ For daily insights and ideas on peak performance: https://www.linkedin.com/in/ryanhanley** ✅ Subscribe to the YouTube show: https://youtube.com/ryanmhanley Connect with David on LinkedIn: https://www.linkedin.com/in/davidgritz/ Our enlightening conversation peels back the layers of how MGAs and MGUs are revolutionizing insurance, offering targeted risk solutions and reshaping the industry for independent agents and consumers alike. Hear firsthand about the incubator-like MGA lab where innovation thrives, and the transformative impact these entities have on both commercial and personal insurance realms. Navigating the tech sphere's entrepreneurial waters can be a tumultuous journey, one that often serves up equal parts laughter and frustration. We swap stories of customer service mishaps that remind us of the importance of accessibility and efficiency—key ingredients to a successful InsurTech venture. The dialogue veers into the potential of artificial intelligence and the seamless integration that entices even investors to become customers, as exemplified by the ease of policy purchases with companies like Chase.  The insurance world is a complex tapestry, but this episode cuts through the intricacy with precision, revealing how aspiring MGA businesses can scale and prosper. From the nitty-gritty of actuarial strategies to the tactical maneuvers of geographic expansion, the keys to a thriving MGA enterprise are laid bare. And for those eager to dip their toes into the InsureTech revolution, we extend a warm invitation to join the vibrant community at InsurTechNY, your launchpad for networking and innovation in the heart of New York. Learn more about your ad choices. Visit megaphone.fm/adchoices

Unlock the secrets behind the burgeoning InsurTech industry with David Gritz, the co-founder and managing director of InsurTechNY.✅ Join over 5,000 newsletter subscribers: https://go.ryanhanley.com/**✅ For daily insights and ideas on peak performance: https://www.linkedin.com/in/ryanhanley**✅ Subscribe to the YouTube show: https://youtube.com/ryanmhanleyConnect with David on LinkedIn: https://www.linkedin.com/in/davidgritz/Our enlightening conversation peels back the layers of how MGAs and MGUs are revolutionizing insurance, offering targeted risk solutions and reshaping the industry for independent agents and consumers alike.Hear firsthand about the incubator-like MGA lab where innovation thrives, and the transformative impact these entities have on both commercial and personal insurance realms.Navigating the tech sphere's entrepreneurial waters can be a tumultuous journey, one that often serves up equal parts laughter and frustration. We swap stories of customer service mishaps that remind us of the importance of accessibility and efficiency—key ingredients to a successful InsurTech venture.The dialogue veers into the potential of artificial intelligence and the seamless integration that entices even investors to become customers, as exemplified by the ease of policy purchases with companies like Chase. The insurance world is a complex tapestry, but this episode cuts through the intricacy with precision, revealing how aspiring MGA businesses can scale and prosper. From the nitty-gritty of actuarial strategies to the tactical maneuvers of geographic expansion, the keys to a thriving MGA enterprise are laid bare.And for those eager to dip their toes into the InsureTech revolution, we extend a warm invitation to join the vibrant community at InsurTechNY, your launchpad for networking and innovation in the heart of New York.Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:    Bri: Hello, I have a friend who was recently diagnosed with MGUS (monoclonal gammopathy) a condition in which an atypical protein is found in the blood and you have a increased risk of having cancer in the future. If this were you, what would you do? Or what path would you start looking down?   Alicia: A holistic chiropractor informed us that our 6 year old son has a hiatal hernia. His symptom is a cough at night after he's been asleep about an hour that eventually progresses to him throwing up. After that he's able to return to sleep. This used to happen a few times a year and now it's just been once so far this winter. Please explain what a hiatal hernia is, if it's common in children, and how we can help him.   HC: Hello Dr. Cabral, Thank you for all you do for your community. I appreciate your selflessness and committment to inform us on real truths of healing!! Do you any knowledge on antioxidant Carbon 60? I have been looking at product (Carbon360) and would appreaciate your feedback. THank you again for all you do!!!!   Heather: Hey doc! Thanks as always for taking the time to answer our questions. Could you talk more in-depth about Beau's lines (the horizontal dents in nails that make them look warp-liked)? I listened to your podcasts on nails and you briefly mentioned these lines mean digestive-based issues. I've gone through the CBO Protocol & Gut Finisher, did a Food Sensitivity test & confirmed I only have a moderate sensitivity to rye & miso. The Beau's lines weren't something I noticed until recently when they started appearing on my fingernails but now I realize I've had them on my toenails for quite some time, otherwise, I would have brought it up to my health coach at the time I was working through the CBO. Thanks again!   Sienna: Hi doctor Cabral, I (47F) would love to do a 3-day water fast for health benefits, but without messing up my hormones and losing muscle. What would be the best way to approach this? Thanks so much for your answer! Sienna   Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/2955 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

A look at Multiple Myeloma (including MGUS), covering pathophysiology as well as signs and symptoms of multiple myeloma (CRAB criteria). Also includes the diagnostic criteria and treatment.Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Multiple Myeloma?0:21 Multiple Myeloma Pathophysiology 1:34 Plasma Cell Dyscrasias2:57 Multiple Myeloma Symptoms5:59 Multiple Myeloma Causes & Risk Factors6:51 Multiple Myeloma Diagnosis7:11 Multiple Myeloma Diagnostic Criteria7:38 Multiple Myeloma TreatmentReferencesJames R. Berenson - **MSD Manual Pro (2023) Multiple Myeloma. Available at https://www.msdmanuals.com/professional/hematology-and-oncology/plasma-cell-disorders/multiple-myelomaSara A. Albagoush; Cameron Shumway; Alexandre M. Azevedo (2023) Multiple Myeloma. Available at https://www.ncbi.nlm.nih.gov/books/NBK534764International Myeloma Foundation (2021) What Are MGUS, Smoldering Multiple Myeloma, and Active Myeloma? Available at https://www.myeloma.org/what-are-mgus-smm-mmS. Vincent Rajkumar (2022) Smoldering multiple myeloma current treatment algorithms. Available at https://www.nature.com/articles/s41408-022-00719-0/Sumana Kundu (2022) Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management. Available at https://www.cureus.com/articles/86261-multiple-myeloma-and-renal-failure-mechanisms-diagnosis-and-management#!/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. 

When discussing Osteoporosis treatment, your physician will most likely prescribe some medications. With the different drugs out there, how do you know which one to take? Is it safe if you have other medical conditions? What are the long-term side effects? Which is a better brand? And the list goes on.   Today, I have someone who will answer your questions about Osteoporosis medications to put your mind at ease.   Dr. R. Keith McCormick is a chiropractic physician specializing in the management of patients with osteoporosis. He is the author of the recently released book Great Bones: Taking Control of Your Osteoporosis and The Whole Body Approach to Osteoporosis.    Sports have always played a vital part in Dr. McCormick's life. He is the former U.S. record holder for the most points scored in a pentathlon competition. Dr. McCormick continues to compete in triathlons of all distances and has completed six Ironman competitions, five of them after recovering from multiple osteoporosis-related fractures.   So, if you have questions about Osteoporosis medications, listen to this informative episode of the Happy Bones, Happy Life podcast!    “I always talk about medications as being a short-term solution to a long-term issue. And that is, when you're taking the medications, all that time you're (also) doing things to improve your overall bone health—your diet and supplements, all that.” - Dr. R. Keith McCormick   In this episode: - [02:10] - How long can you stay on Prolia? - [05:31] - How can I prevent the rebound effect from quitting Prolia? - [10:47] - Should I continue using Prolia?  - [12:08] - How long do most people use Prolia? - [13:56] - How to achieve long-term success in your battle with Osteoporosis  - [17:52] - What can I do to prevent the adverse effects of taking teriparatide? - [19:55] - Forteo vs. Tymlos - [21:59] - What are the effects of MGUS, and is there anything we can do about it? - [24:43] - Can I safely quit taking Prolia with my current medical condition? - [26:57] - Will mast cell activation affect your bone health? - [27:36] - I have Osteoporosis and breast cancer. My oncologist prescribed Raloxifene. I'm not sure about taking it. Who do I see for testing and the meds? - [33:42] - I used to take Forteo, then stopped. If I use it again, will it have the same effect as building bone density the first year? - [37:32] - It's important to do these things before taking tests and medications - [42:21] - I'm 74 and have scoliosis. My doctor has recommended I take either Forteo or Prolia. Which drug should I take? - [44:15] - How important is Vitamin K2 to your bone health?   Resources mentioned - The Happy Bones Club - https://www.happyboneshappylife.com/bones-club - Great Bones: Taking Control of Your Osteoporosis - R. Keith McCormick, DC - https://www.osteonaturals.com/product-page/great-bones-taking-control-of-your-osteoporosis - Consult with Dr. McCormick - https://www.osteonaturals.com/consult-osteonaturals   More about Margie - Website - https://margiebissinger.com/  - Facebook - https://www.facebook.com/p/Margie-Bissinger-MS-PT-CHC-100063542905332/  - Instagram - https://www.instagram.com/margiebissinger/?hl=en    DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast. *In compliance with the FTC guidelines, please assume the following about links on this site: Some of the links going to products are affiliate links of which I receive a small commission from sales of certain items, but the price is the same for you (sometimes, I even get to share a unique discount with you). If I post an affiliate link to a product, it is something that I personally use, support, and would recommend. I personally vet each and every product. My first priority is providing valuable information and resources to help you create positive changes in your health and bring more happiness into your life. I will only ever link to products or resources (affiliate or otherwise) that fit within this purpose.  

BUFFALO, NY- January 22, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.” Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the bone marrow. In spite of recent advances in the field of MM, the disease has remained incurable. MM is preceded by a premalignant state known as monoclonal gammopathy of undetermined significance (MGUS), with a risk of progression to MM of 1% per year. Establishing a scalable approach that refines the identification of MGUS patients at high risk of progression to MM can transform the clinical management of the disease, improve the patient's quality of life, and will have significant socioeconomic implications. In this new perspective, researchers Bilal M. El-Masri, Benedeta Leka, Fatima Mustapha, Michael Tveden Gundesen, Maja Hinge, Thomas Lund, Thomas L. Andersen, Marta Diaz-delCastillo, and Abbas Jafari from the Danish Spatial Imaging Consortium, University of Southern Denmark, University of Copenhagen, University of Aarhus, Odense University Hospital, and Lillebaelt Hospital provide evidence that changes in the bone marrow adipose tissue (BMAT) provide an early sign for progression from MGUS to MM. “We employed AI-assisted histological analysis of unstained bone marrow biopsies from MGUS subjects with or without progression to MM within 10 years (n = 24, n = 17 respectively).” Although the BMAT fraction was not different between the two groups, bone marrow adipocyte (BMAd) density was decreased in MGUS patients who developed MM, compared to non-progressing MGUS patients. Importantly, the distribution profile for BMAd size and roundness was significantly different between the two groups, indicating a shift toward increased BMAd size and roundness in MGUS patients who developed MM. These early changes in the BMAT could serve as valuable early indicators for the transition from MGUS to MM, potentially enabling timely interventions and personalized treatment strategies. “[...] the AI-based approach for histological characterization of unstained bone marrow biopsies is cost-effective and fast, rendering its clinical implementation feasible.” DOI - https://doi.org/10.18632/oncotarget.28548 Correspondence to - Abbas Jafari - ajafari@sund.ku.dk, Marta Diaz-delCastillo - marta@forens.au.dk, and Thomas L. Andersen - thomas.levin.andersen@rsyd.dk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28548 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, multiple myeloma, MGUS, bone marrow adipocyte About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1.      New diagnostic criteria for light chain MGUS (IStopMM):              https://ash.confex.com/ash/2023/webprogram/Paper188547.html             https://ash.confex.com/ash/2023/webprogram/Paper182661.html2.     PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper191911.html 3.     ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper177546.html 4.     Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma: https://ash.confex.com/ash/2023/webprogram/Paper180766.html 5.     GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma) https://ash.confex.com/ash/2023/webprogram/Paper178835.html 6.     Overall survival results of KarMMa-3 trial https://ash.confex.com/ash/2023/webprogram/Paper178933.html 7.      GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients: https://ash.confex.com/ash/2023/webprogram/Paper179866.html      

This Good Practice Paper podcast provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.  

Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an algorithm with Dr. S. Vincent Rajkumar. We covered MGUS and smoldering myeloma in great detail, following with how these patients should be monitored and if any of these patients should be treated. Dr. S. Vincent Rajkumar is a world-renowned physician who specializes in plasma cell disorders - Professor of Medicine at the Mayo Clinic Comprehensive Cancer Center.

Jeff Radke is CEO and Co-Founder of Accelerant, a technology-fueled insurance platform that empowers MGUs to more effectively and confidently serve small and medium enterprises. He has spent his career working across all areas of the insurance value chain, from underwriting to reinsurance in global markets. Prior to Accelerant, Jeff spent a decade at Argo Group International Holdings, but he became frustrated with thelegacy system's antiquated technology and emphasis on maintaining their position in the value chain over doing right by the customer. This inspired him to co-found Accelerant to enable data-driven innovation and collaboration that puts customers first. Accelerant rebuilds the way that underwriters share and exchange risk to improve outcomes for everyone, with a focus on the SMBs that power our global economy and their niche insurance needs. Highlights from the Show Jeff started his career in Reinsurance, which gave him an interesting perspective on insurance having looked at it from the end of the value chain Accelerant runs a risk exchange, meaning they connect MGAs/MGUs/Program Administrators (who they call Members) with risk capital on the other side of the platform that likes the kinds of Specialty risks these members are writing In between those parties, Accelerant's platform tries to make the regulatory and system complications as uncomplicated as possible by solving for them for their members It's almost the opposite of what a fronting carrier is, and is more of a portfolio manager of risk They try to provide stability of capital and appetite and the ability to capitalize on every opportunity an MGA finds They've also become a way for existing insurers to get into the E&S or Specialty space without having to build the technology stack, distribution relationships or underwriting talent It's very hard to build a business that can write large, esoteric, specialty risks and the higher volume E&O/PL, BOP and GL It's a completely different human skillset and tech capability to keep a tight watch and understanding on how small, Specialty Lines portfolios change over time They do monthly deep dives with their members to see if anything has changed with appetite, underwriting review, etc. to see if there's a potential driver of performance changes so they can react before it's ballooned out of control Traditionally, program administrators haven't gotten the detailed data they need on things like regulatory compliance, loss trends, filings, etc., and Accelerant has worked to be as transparent as possible rather than treating their information as proprietary or something not to share One reason Jeff thinks E&S will stay strong and not just be a fill-in for what can't go Admitted at the moment is because of the need to keep flexing on product and rate at a speed that the regulatory path cannot keep up with, especially with resource constraints there This episode is brought to you by The Future of Insurance Volume III. The Collaborators, part of the Future of Insurance thought leadership series (future-of-insurance.com) from Bryan Falchuk. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

Tony chats with Will Ross, Co-Founder and CEO at Federato. Bringing concepts from portfolio optimization and mixing them with AI and Machine Learning, Federato's RiskOps is an underwriting platform for carriers, MGAs and MGUs providing real-time risk selection and portfolio insights to empower underwriters to balance their book of business and make better underwriting decisions.Will Ross: https://www.linkedin.com/in/williamross826/Federato: https://www.federato.ai/Video Version: https://youtu.be/0cY7D_uFO1w

Sandra Mazzoni, DO, a hematologist at Cleveland Clinic Taussig Cancer Institute joins the Cancer Advances podcast to talk about monoclonal gammopathy of undetermined significance, known as MGUS. Listen as Dr. Mazzoni talks about this abnormal protein and explains when we can still effectively treat patients before it hits all the criteria for becoming multiple myeloma.

A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.” In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain from SUNY Upstate Medical University, University of Texas MD Anderson Cancer Center, Monmouth Medical Center, University of Balamand, Cleveland Clinic Ohio, UnityPoint Methodist, Houston Methodist Cancer Center, and Cleveland Clinic Florida report the literature on the latest treatment updates of Systemic Light chain (AL) amyloidosis and the ongoing clinical trials highlighting the future treatments. “In this manuscript, we discuss the general approach towards treating patients with amyloidosis and dive into the future perspectives in this multi-systemic disease.” Systemic AL amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early can lead to organ failure and potentially death. The renal system along with the cardiovascular system are the most common organs involved, but other organs such as the gut and liver can be involved as well. The initial evaluation of patients requires confirming the diagnosis with tissue biopsy and staining with Congo red followed by confirmatory typing with mass spectrometry of the Congo red positive tissue. Then establishing the extent of the organs involvement by various staging and biomarkers testing. The treatment options and the tolerability of therapy depend on the disease staging, frailty and co-morbidities. The autologous hematopoietic cell transplantation (HCT) after high dose melphalan therapy is an effective strategy which is usually done after initial bortezomib induction therapy. Unfortunately, most systemic AL amyloidosis patients are not candidates for HCT due to frailty, old age, multi-organ involvement, and renal or heart failure at the time of diagnosis. While it is widely accepted that the patients need to be treated until they achieve complete hematologic response, the maintenance therapy after HCT is not well established in AL amyloidosis. “The relationship between AL amyloidosis and MGUS is less clear, but some studies suggest that the risk of developing AL amyloidosis may be increased in patients with MGUS. It is important for patients with these conditions to undergo regular monitoring and evaluation for signs of AL amyloidosis, as early diagnosis and treatment can improve outcomes.” DOI - https://doi.org/10.18632/oncotarget.28415 Correspondence to - Chakra P. Chaulagain - chaulac@ccf.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28415 Keywords - amyloidosis, management About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

This week's episode will be an introduction to plasma cell dyscrasias. We will cover the diagnostic criteria for MGUS and Smoldering Myeloma as well as introduce Multiple Myeloma.

Top claims challenges for MGAs/MGUs and how to overcome them

Lynda A. Bennett and Eric Jesse continue their discussion with Michael Wakefield from CAC Specialty about MGUs and MGAs in the context of reps and warranties insurance. They address how MGU/MGA-negotiated policies can be insured by multiple insurers that share a percentage of the policy limit, plus the role of the MGU or MGA in the claim process, what incentivizes these entities to be effective advocates on behalf of policyholders, and the risks involved for policyholders choosing MGUs or MGAs. Speaker:Lynda A. Bennett, Partner and Chair, Insurance Recovery Eric Jesse, Partner, Insurance Recovery Michael Wakefield, Executive Vice President – Transactional Insurance Practice Leader, CAC Specialty

In today's episode, Lynda Bennett is joined by Eric Jesse, Partner in Lowenstein's Insurance Recovery Group, and Michael Wakefield, Transactional Insurance Practice Leader from CAC Specialty to explore the differences between traditional insurers that issue rep and warranty policies and other types of transactional risk policies, and MGUs and MGAs, otherwise known as managing general underwriter or agents. How do MGUs and MGAs differ from traditional insurers and from each other, and what are the respective benefits of each for different types of claims? Speaker:Lynda A. Bennett, Partner and Chair, Insurance Recovery Eric Jesse, Partner, Insurance Recovery Michael Wakefield, Executive Vice President – Transactional Insurance Practice Leader, CAC Specialty

In this continuation of our myeloma series, we discuss the progression of MGUS & smoldering myeloma to multiple myeloma. We also outline how to risk stratify a patient with multiple myeloma and gauge their response to treatment. Content:-What is the natural progression from MGUS to smoldering myeloma to multiple myeloma?- How do we risk stratify patients with a new myeloma diagnosis? - What is the role of FISH/karyotype in risk stratification in myeloma?-How do we gauge disease response in myeloma?- How do we define disease progression?- How do we define treatment response? - What is the role of minimal residual disease (MRD) in myeloma? Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In today's episode, we continue our myeloma series, this time we'll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!Content:- Defining MGUS- Discussing risk of progression of MGUS to MM- How to interpret free light chains in renal failure- How do we monitor MGUS patients?- When do we do additional testing in MGUS?- What is smoldering myeloma?- What are myeloma defining events?- How do we risk stratify SM patients?- How do we monitor SM patients? Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper159606.htmlhttps://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.https://ash.confex.com/ash/2022/webprogram/Paper170166.htmlLink to the model: https://istopmm.com/riskmodel/ 3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma https://ash.confex.com/ash/2022/webprogram/Paper159357.html 4. Talquetamab: Phase 1/2 results from Monumental-1https://tinyurl.com/kwn9en9mhttps://www.nejm.org/doi/full/10.1056/NEJMoa2204591 5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosishttps://tinyurl.com/yrvjjruv 6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myelomahttps://tinyurl.com/bde84xuw 7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Studyhttps://ash.confex.com/ash/2022/webprogram/Paper159711.html 8. Three excellent abstracts from IstopMM:Is MGUS associated with autoimmune disease?https://tinyurl.com/5dafcz2wIs isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?https://tinyurl.com/4tut3reaIs MGUS associated with CKD?https://tinyurl.com/34swvkj9 9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trialshttps://tinyurl.com/2n78yzfh 10. Surrogacy between PFS and OS in Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper163855.htmlhttps://pubmed.ncbi.nlm.nih.gov/36495317/

In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma cell dyscrasias and having our initial discussion about monoclonal gammopathy of undetermined significance (MGUS). Contents:- What is a plasma cell ?- What is a plasma cell dyscrasia?- What is an "SPEP"?-What is "immunofixation"?-What are "serum free light chains"?-Checking UPEP-Does everyone need a bone marrow biopsy and/or additional workup?-What is MGUS?Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Host: Darryl S. Chutka, M.D. (@ChutkaMD) Guest: Wilson I. Gonsalves, M.D. Monoclonal gammopathies represent abnormal proteins produced by plasma cells. The most common monoclonal gammopathy is monoclonal gammopathy of undetermined significance or MGUS. While MGUS itself is not a malignancy and doesn't require treatment, patients with MGUS have an increased risk of developing a variety of hematologic malignancies and therefore do require surveillance. The topic for today's podcast is monoclonal gammopathy of undetermined significance and our guest is Wilson I. Gonsalves, M.D., a hematologist and oncologist from the Division of Hematology at the Mayo Clinic. We'll discuss how to diagnose MGUS, who is more likely to develop this condition and how patients with it should be followed.  Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Today's guest is Miles Wuller, President and CEO of Ryan Specialty Underwriting Managers, the underwriting arm of Ryan Specialty. As such Miles is responsible for more than 20 MGUs, offering more than 150 lines of business and employing around 550 staff in 27 offices who wrote $2.4bn of Gross Premium in 2021. This means he has a fantastic view of the market and where all its pressure points are to be found. A listen to this podcast will definitely get you right up to speed with all the cut and thrust of US and international specialist lines. But Miles is also a great business builder and manager and in our chat we really get to the heart of the Ryan Specialty modus operandi. For instance, how does Miles keep an incredibly diverse business with multiple brands, housing a huge variety of underwriting entrepreneurs within a core strategic Ryan Specialty identity and culture? Very few executives have to maintain and incentivise innovation and creativity on such a scale while at the same time keeping on top of all the compliance and reporting demands of a major unit of a fast-growing public company. Miles exudes a calm competence at every turn and it is abundantly clear that he thinks really deeply about the industry. For instance his thoughts on the effects of inflation on the sector, cyber insurance, his business's relationship with technology, and the burgeoning hybrid carrier phenomenon are highly insightful. And that's just to mention four topics among many more. Suffice to say that I learnt an awful lot during this interview and I think that you will too. NOTES: A couple of property abbreviations: TIV=Total Insured Values. SOV=Statement of Values Also a request. If anyone can tell me any significant difference between a Managing General Agent (MGA) and a Managing General Underwriter (MGU), please let me know. After 30 years of head-scratching, I think they are completely interchangeable transatlantic versions of each other. LINKS We thank our naming sponsor AdvantageGo: https://www.advantagego.com/ We also thank this Episode's advertising supporter Oxbow Partners https://oxbowpartners.com/

Welcome to Insurance Covered, the podcast that covers everything insurance. In this episode Peter is joined by Richard Clapham, CEO of DUAL, and together they discuss the role of the modern MGA. In this episode we discuss:How the role of an MGA has changed in recent yearsThe difference between MGAs, MGUs, coverholders & delegated authorityThe relationship between an insurer and an MGAHow the DUAL model differs to other MGAsHow MGAs can adapt to survive and thrive in the current market.We hope you enjoyed this episode, if you did please subscribe to stay up to date with future episodes. See acast.com/privacy for privacy and opt-out information.

Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple... The post ASH 2021: evaluating the impact of screening for MGUS and SMM appeared first on VJHemOnc.

Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple... The post ASH 2021: evaluating the impact of screening for MGUS and SMM appeared first on VJHemOnc.

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society's Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Bristol Myers Squibb

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society's Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Bristol Myers Squibb

Multiple myeloma is a hematologic malignancy characterized by abnormal plasma cells in the bone marrow, with potential uncontrolled growth causing destructive bone lesions, kidney injury, anemia, and hypercalcemia. Edward Libby, MD, of the University of Washington, joins JAMA Associate Editor Ethan Basch, MD, of the University of North Carolina, for a discussion of the diagnosis, complications, and management of myeloma, as well as the related conditions of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. Related Content: Diagnosis and Management of Multiple Myeloma Patient Information: Multiple Myeloma

Show #1330 If you get any value from this podcast please consider supporting my work on Patreon. Plus all Patreon supporters get their own unique ad-free podcast feed. Good morning, good afternoon and good evening wherever you are in the world, welcome to EV News Daily for Tuesday 4th January. It's Martyn Lee here and I go through every EV story so you don't have to. Thank you to MYEV.com for helping make this show, they've built the first marketplace specifically for Electric Vehicles. It's a totally free marketplace that simplifies the buying and selling process, and help you learn about EVs along the way too. WILL TESLA SELL OVER 1.5 MILLION ELECTRIC CARS IN 2022? - The starting point is over 936,000 in 2021. Assuming that the rate of 300,000+ units per quarter would be maintained for all of 2022, the company would be at 1.2 million total. - In terms of new plants, according to the latest reports, Tesla Giga Austin in Texas should start production soon, and Tesla Giga Berlin in Grünheide near Berlin, Germany also appears ready to start production. - If those two new plants would add 300,000 together, with a maintained rate from Q4 by the plants in California and China, the total would then exceed 1.5 million. That's 600,000 additional BEVs in a year. Original Source : https://insideevs.com/news/558267/tesla-ev-sales-2022-forecast/ 4 MILLION PEOPLE WILL DRIVE TESLAS BY THE END OF 2022 - According to our data, Tesla has delivered by the end of 2021 more than 2,335,000 all-electric cars, which is by way more than anyone else. - This number includes more than half a million Model S/Model X and more than 1.8 million Model 3/Model Y. - considering the recent production rate of 308,600 units in Q4 2021, we should see 2.5 million total and 2 million Model 3/Model Y in February/March. - Assuming 1.5 million new Tesla cars in 2022, there would be over 3.8 million total, maybe more, depending on what the current year will bring. 4 million Teslas would be a tremendous achievement. Original Source : https://insideevs.com/news/558272/4-million-teslas-2022-forecast/ FORD F-150 LIGHTNING PRICING ANNOUNCED - Ford announced pricing and more details about the Ford F-150 Lightning, which later this week will be available for order (by reservation holders, in batches). As we know, there are four versions of the truck, Pro, XLT, Lariat and Platinum. Production of all four types will begin in Spring. MSRP price of Ford F-150 Lightning in the U.S.:  Pro: $39,974 XLT: $52,974 Lariat: $67,474 Platinum: $90,874 - The Pro version comes with the Standard Range Battery for up to 230 miles (370 km) of expected EPA range. There is also the Extended Range Battery that extends the range up to 300 miles (483 km) - optional in the case of XLT and Lariat ($10,000), and standard in the Platinum trim. - there is a Pro version with the Extended Range Battery ($10,000 option) but it's envisioned only for fleets. - According to the previous report, the difference between the two battery options is 33 kWh of usable battery capacity:  Standard Range Battery: 98 kWh Extended Range Battery: 131 kWh Original Source : https://insideevs.com/news/558716/ford-f150-lightning-pricing/ F-150 Lightning Options Add Up To Rivian Territory Real Fast - The Lightning really begins to pale when you start adding luxuries, like heated seats. Butt warmers require equipment group 312A, which also includes Ford's CoPilot 360 2.0 Level 2 driver assist suite, a power tailgate and a heated leather steering wheel in addition to other, less noteworthy bells and whistles. That's another $9,500 on the sticker. - Couple the extended range battery with 312A to get the Lightning relatively close to the R1T's base spec in terms of interior comforts and performance, and you're spending $74,169 including destination. - Poking around both electric pickups' build-and-price tools, here's the impression I get: the F-150 Lightning is obviously the more affordable truck and actually attainable for those with less to spend. However, if you plan on checking boxes for options, the R1T will quickly become the better value. For $60K-$70K, it's the more compelling package. Original Source : https://jalopnik.com/here-are-the-options-to-check-if-you-want-your-ford-lig-1848300647 NORWAY SETS NEW EV SALES RECORD IN 2021, WANTS EVEN MORE IN 2022 - Norway set another record in 2021, and it is about electric vehicles again. Despite the global chip crisis, electric vehicle sales dominated the market and made up 64.5 percent of sales in 2021, which is the highest percentage ever achieved by them. - The country's record month in terms of EVs sales market share was September, with 77.5 percent of all vehicles sold in the country being battery electric vehicles. - Tesla is the most popular brand in Norway, beating Volkswagen's 11-year success story. The Model 3 was the number one favorite for Norwegian customers, followed by Toyota's RAV4 EV, and Volkswagen's ID.4. Tesla's Model Y achieved fourth place. Original Source : https://www.autoevolution.com/news/norway-sets-new-ev-sales-record-in-2021-wants-even-more-in-2022-178213.html TESLA CYBERTRUCK ORDER PAGE NO LONGER MENTIONS A 2022 PRODUCTION ESTIMATE - Tesla quietly updated the Cybertruck's order page, removing references to the vehicle's expected 2022 production date. The update may have been implemented during the final weeks of 2021. - Previously, the all-electric pickup truck's order page featured a simple note stating that customers will be able to “complete their (your) configuration as production nears in 2022.” Tesla's Cybertruck order page today simply informs customers that they will be able to complete their vehicle configurations as production nears. Original Source : https://www.teslarati.com/tesla-cybertruck-2022-release-date-update/ DAKAR 2022, STAGE 3: SAINZ SCORES FIRST WIN FOR ELECTRIC AUDI - Carlos Sainz claimed Audi's maiden stage victory in the Dakar Rally on Tuesday, - The result marked the 40th stage win for Sainz as well as the first for an electric prototype in the top cars division, with Audi running three MGUs on its RS Q e-tron using technology it developed in Formula E. Original Source : https://www.motorsport.com/dakar/news/dakar-sainz-audi-first-stage-win/7076874/ WALLBOX INTRODUCES QUASAR 2 AT CES 2022 - As well as enabling EV owners to charge and discharge their electric vehicle to power their home or the grid, Wallbox's latest innovation is designed to give EV drivers the ability to isolate their home from the grid and use their EV for backup power during a blackout. - With Blackout Mode, users are able to use their EV battery to power their home in the event of a power outage, even those caused by natural disasters. Quasar 2 seamlessly transitions a home to vehicle energy when the power goes out. Depending on the car and energy usage Quasar 2 is expected to be able to power a home for more than three days during a blackout based on an average household's critical consumption. Original Source : https://www.businesswire.com/news/home/20220103005080/en/ STOREDOT SECURES $80 MILLION IN FUNDING - Israeli battery developer StoreDot has announced the first close of its Series D funding round of up to $80 million, the majority of which has already been secured. - The Israeli company had demonstrated an interim step in 2019 showcasing that their technology could charge the battery of an electric scooter in five minutes. The first development samples were demonstrated to potential partners in early 2021. Then, in May 2021, the cooperation with EVE Energy was announced, which includes the production of the cells from 2024. - The company's fast-charging electric car battery cells with a silicon-dominated anode, which should also enable high energy densities. Original Source : https://www.electrive.com/2022/01/04/storedot-secures-80-million-in-funding/ BUDAPEST ORDERS 48 E-BUSES FROM SOLARIS & SKODA - ELECTRIVE.COM - A consortium consisting of Solaris Bus & Coach and Skoda Electric has received an order for 48 battery-electric trolleybuses from Budapest. The current order of 12- and 18-metre buses goes back to a framework agreement from 2014, which has now been completely fulfilled with the order. - With the 48 trolleybuses now on order, the total number of 108 vehicles agreed in 2014 has been reached. The order is divided into 12 Trollino 12s and 36 Trollino 18s, i.e. the 18-metre articulated bus version. Solaris says that the 48 buses are to be delivered by autumn 2022. - The batteries will enable the trolleybuses for Budapest to travel at least four kilometres without overhead lines. Original Source : https://www.electrive.com/2022/01/02/budapest-orders-48-e-buses-from-solaris-skoda/ KANSAS CITY INTERNATIONAL AIRPORT INSTALLS WIRELESS CHARGERS Original Source : https://www.prnewswire.com/news-releases/kansas-city-international-airport-installs-wireless-chargers-by-momentum-dynamics-becoming-first-airport-with-wireless-charging-for-its-electric-bus-fleet-301450602.html APPLE'S LATEST PATENT DROPS A HINT AT HOW ITS ELECTRIC CAR MAY GET CHARGED Original Source : https://www.businessinsider.in/business/auto/news/apples-latest-patent-drops-a-hint-at-how-its-electric-car-may-get-charged/articleshow/88660724.cms ENPHASE CELEBRATES THE NEW YEAR BY ENTERING THE EV CHARGING MARKET Original Source : https://pv-magazine-usa.com/2022/01/03/enphase-celebrates-the-new-year-by-entering-the-ev-charging-market/ 91% OF EV OWNERS SAY THEY WILL NEVER BUY A PETROL OR DIESEL CAR AGAIN   Original Source : https://www.thisismoney.co.uk/money/cars/article-10367579/91-EV-owners-say-never-buy-petrol-diesel-car-again.html QUESTION OF THE WEEK WITH EMOBILITYNORWAY.COM This question was suggested by Joshua Pritt: “If you live in an apartment or condo or otherwise can't charge at home, how do you charge? Is it a terrible inconvenience or do you have a simple routine to charge during your shopping trips?” Email me your answer now: hello@evnewsdaily.com It would mean a lot if you could take 2mins to leave a quick review on whichever platform you download the podcast. And  if you have an Amazon Echo, download our Alexa Skill, search for EV News Daily and add it as a flash briefing. Come and say hi on Facebook, LinkedIn or Twitter just search EV News Daily, have a wonderful day, I'll catch you tomorrow and remember…there's no such thing as a self-charging hybrid. PREMIUM PARTNERS PHIL ROBERTS / ELECTRIC FUTURE BRAD CROSBY PORSCHE OF THE VILLAGE CINCINNATI AUDI CINCINNATI EAST VOLVO CARS CINCINNATI EAST NATIONAL CAR CHARGING ON THE US MAINLAND AND ALOHA CHARGE IN HAWAII DEREK REILLY FROM THE EV REVIEW IRELAND YOUTUBE CHANNEL RICHARD AT RSEV.CO.UK – FOR BUYING AND SELLING EVS IN THE UK EMOBILITYNORWAY.COM

Blain Murphy is an academic psychologist from Belfast, Northern Ireland. In this episode, we discuss his PhD which investigated the psychological impact of a diagnosis of MGUS on patients' quality of life. It's a real eye opener and a must listen. You can find Blain's paper here: https://www.ejoncologynursing.com/article/S1462-3889(21)00007-7/fulltext. Please leave us a review and share the show on Twitter

Welcome back for another episode of Get Checkered! This week, the girls go over several weekly headlines and do a special on Motor Generator Units (MGUs). Some of the weekly headlines include topics such as the Giovinazzi and Alfa Romeo saga, Mercedes' power unit performance, VW group entering into the F1 engine world, and the GP announcement for Qatar 2021 (and the next 10 years). MGUs have been in the news quite a fair bit lately, so we thought we should dive in and find out more about them. What are they? Why are they so important? Check out this episode to find out.

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answered: Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?In this podcast, Mateos discusses the progression of monoclonal gammopathy of undetermined significance (MGUS) and SMM to MM from a molecular point of view. She explains the 2/20/20 risk stratification model for SMM, and the phase III clinical trials that have demonstrated a benefit in treating patients with high-risk SMM to delay the progression to overt MM. In her road map to cure MM, early treatment of SMM is a crucial step, and she presents two curative approaches being currently investigated in clinical trials. Hosted on Acast. See acast.com/privacy for more information.

Featuring an interview with Dr Morie A Gertz, including the following topics: Recent advances in the treatment of amyloid light chain (AL) amyloidosis (0:00) Case: A woman in her late 70s receiving medical care for monoclonal gammopathy of undetermined significance (MGUS) is diagnosed with AL amyloidosis (22:12) Case: A man in his late 70s being monitored for multiple myeloma after a diagnosis of smoldering multiple myeloma is found to have AL amyloidosis (25:04) Case: A man in his early 70s with amyloidosis with peripheral neuropathy receives a misdiagnosis of MGUS (26:29) Pathophysiology and diagnosis of AL amyloidosis (28:32) Case: A woman in her late 70s being monitored for MGUS is found to have AL amyloidosis (34:37) Design, eligibility criteria and key endpoints of the Phase III ANDROMEDA study evaluating subcutaneous daratumumab in combination with CyBorD versus CyBorD alone for patients with newly diagnosed AL amyloidosis (39:22) Activity and tolerability of pomalidomide, venetoclax or isatuximab in patients with AL amyloidosis (47:48) Mechanism of action and efficacy of CAEL-101, an antibody targeting light chain amyloid fibrils, for AL amyloidosis (53:48) Selection and sequencing of therapy for patients with AL amyloidosis (56:17) CME information and select publications

In this podcast, Dr Gerard Crotty, Consultant Hematologist explains Monoclonal Gammapathy of Undermined Significance (MGUS) a non-cancerous condition of the plasma cells and the slow growing cancerous process or early form of myeloma, Smouldering Multiple Myeloma. Dr Crotty explains how treatment outside a clinical trial is not indicated in patients with either condition, however close monitoring is required. For patients living with MGUS only a small no of patients will progress to Multiple Myeloma and will require treatment. For patients with Smouldering Multiple Myeloma abnormal cells can be detected in the bone marrow and an abnormal protein can be detected in the blood or urine but patients have none of the typical symptoms of active disease and monitoring regularly for signs that may indicate progression to active disease is the mainstay of management. Understanding MGUS or SMM can be challenging for patients, Dr Crotty highlights the key symptoms patients need to report to their treating team. Multiple Myeloma Ireland: Website Facebook Twitter This podcast has been produced by Fuzion Communications.

We are continuing our conversation with Ms. Joan Rodriguez  as our patient advocate for Mutiple Myeloma Awareness Month! She was such a powerhouse and had so many #gems to share with us about her journey with Multiple Myeloma. Ms. Joan says "Educating yourself is empowering" and she exemplifies this concept with her own story.  Joan Rodriguez is a native Bostonian. In 2003, she was diagnosed with MGUS and had progressive neuropathy. After a less than pleasant experience with one doctor, she switched to another who honored her request to never discuss her charts with the previous physician. After initial rounds of treatments, she started to get better and her symptoms decreased so that she was able to progress from using a walker to a cane, but the neuropathy never went away completely and she still has numbness in her feet. In 2016, she progressed to Smoldering Myeloma with markers qualifying her to be high risk.She joined a clinical trial and a myeloma support group at Dana Farber. She is a participant of the Promise Study and will be participating in a future PSA with them. --New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

We were so excited to have Joan Rodriguez on as our patient advocate for Mutiple Myeloma Awareness Month! She was such a powerhouse and had so many #gems to share with us about her journey with Multiple Myeloma. Ms. Joan says "Educating yourself is empowering" and she exemplifies this concept with her own story.  Joan Rodriguez is a native Bostonian. In 2003, she was diagnosed with MGUS and had progressive neuropathy. After a less than pleasant experience with one doctor, she switched to another who honored her request to never discuss her charts with the previous physician. After initial rounds of treatments, she started to get better and her symptoms decreased so that she was able to progress from using a walker to a cane, but the neuropathy never went away completely and she still has numbness in her feet. In 2016, she progressed to Smoldering Myeloma with markers qualifying her to be high risk.She joined a clinical trial and a myeloma support group at Dana Farber. She is a participant of the Promise Study and will be participating in a future PSA with them. --New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

March is Multiple Meyeloma Awareness Month. In this episode, The Docs go over the signs and symptoms of multiple myeloma, how it is diagnosed, and some ways to help lower your risk. Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications.Multiple Myeloma is usually diagnosed in patients in their 60s, but Black patients are often diagnosed a decade earlier. Black patients are also twice as likely to develop multiple myeloma as patients of other races.MGUS (monoclonal gammopathy of undetermined significance): A precursor condition that often precedes a multiple myeloma diagnosis. Common symptoms of multiple myeloma include:   -Bone pain, especially in your spine or chest   -Constipation   -Nausea   -Fatigue   -Weakness or numbness in your legs--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

David Murray, M.D., Ph.D., explains Mayo Clinic Laboratories' innovative approach to screening for plasma cell disorders and monitoring of patients being treated for multiple myeloma. This testing method, called MASS-FIX, employs matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, or MALDI-TOF MS. It offers significant advantages over traditional testing approaches and marks the first major breakthrough in multiple myeloma screening since gel electrophoresis was developed in the 1960s.

Today on MedNet21, we're going to discuss Multiple Myeloma and MGUS.

Dr. Robert Z. Orlowski joins HealthTree Podcast for Multiple Myeloma to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society's Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Karyopharm Therapeutics

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Karyopharm Therapeutics

Recap the top pearls from recent shows on vulvovaginitis, cellulitis and bites, MGUS and the SPEP. Tales from the Curbside (TFTC) is pilot project providing a rapid review of recent Curbsiders episodes. Note: There is no CME for this mini-episode but visit curbsiders.vcuhealth.org to claim credit for #244, #246 and #247. Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Credits Written, Produced and Hosted by: Stuart Brigham MD; Matthew Watto MD, FACP; Paul Williams MD, FACP Infographics by: Kate Grant MBChb, MRCGP, Beth Garbitelli and Nora Taranto MD Cover Art: Matthew Watto Editor: Matthew Watto MD (written materials); Clair Morgan of nodderly.com Sponsor: The American College of Physicians Join us for ACP Internal Medicine Meeting 2021: Virtual Experience for 3 days of interactive, livestreaming education and events April 29 through May 1—plus on-demand post-meeting access to CME credit for up to 3 years. “Early Bird” members get an additional $80 registration discount on top of their member discount. Visit annualmeeting.acponline.org and use the code IM21CURB. Register now—Early Bird savings end January 31st! Time Stamps* *Note: Time Stamps refer to ad free versions. 00:00 Intro, disclaimer, guest bio 02:35 Vulvovaginitis 05:35 Cellulitis and Bites 09:45 SPEP it Up 15:15 Outro

On this episode, Dr. Jorge Castillo (Harvard, Dana Farber) walks us through some immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis--and finally, how to talk to patients about them. If you, like Stuart, have ever wondered what on earth to do with that pesky free light chain ratio or the SPEP that so often gets inboxed to you without explanation, then fear not, Dr Castillo has your back! Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Credits Written and Produced by Nora Taranto MD Infographics by Nora Taranto MD Cover Art by Kate Grant MBChB, MRCGP Hosts: Matthew Watto MD, FACP; Stuart Brigham MD, FACP, Nora Taranto MD Editor: Matthew Watto MD, FACP ; Clair Morgan of nodderly.com Reviewer: Jooho Chung MD, PhD Guest: Jorge Castillo MD Sponsor: Panacea Financial This episode is supported by Panacea Financial, digital banking built for doctors, by doctors. At Panacea Financial you can have your own free personal banker and a support team that works around the clock- just like you do. Open your free checking account today at panaceafinancial.com Panacea Financial, a Division of Sonabank, Member FDIC Sponsor: VCU Health CE We are excited to announce that the Curbsiders are now partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Check out curbsiders.vcuhealth.org and create your account!

This week, Yolanda and I kept it casual. We have no interviewees, but we just missed talking. We had a conversation about whatever struck our fancy.  One thing that came up was smoldering myeloma, MGUS, and the anxiety that comes with not knowing whether you're going to progress to full blown Myeloma.Production note: I apologize for the first 10 minutes of really poor sound quality. My microphone was facing the wrong direction. Sit back, relax, fast forward if you need to, and let us know that you're listening.Support the show (https://www.patreon.com/myelomateam)

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.   These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.   In this episode of HOPA Now, Dr. Kirollos Hanna highlights the fundamentals regarding multiple myeloma, the 14th most common cancer in the U.S. He offers details regarding diagnosis data and risk factors, the pathophysiology and molecular biology of multiple myeloma, the tools used to stage select patients and the importance of patient adherence to varying degrees of therapy regimens.   In this episode you will learn:   Multiple Myeloma: Fundamentals Diagnosis data and figures surrounding multiple myeloma Risk factors for developing multiple myeloma The main differentiating factors for MGUS smoldering and active myeloma Pathophysiology and disease-related symptoms of multiple myeloma C.R.A.B. symptoms, their causes, and common resulting effects Molecular biology of myeloma and cytogenetic abnormality prognostic factors High-risk differentiating factors and the tools used to stage select patients The importance of patient adherence to therapy regimens   Mentioned in This Episode: HOPA   Quotes:   “We know that cytogenetic abnormalities oftentimes have a lot to do with preventing normal differentiation of apoptosis.” — Dr. Kirollos Hanna   “It is very rare or uncommon to see patients have IGM or IGD myeloma, and extremely rare to see patients not have any M proteins present in the blood or the urine.”  — Dr. Kirollos Hanna   “Response criteria ranges anywhere from stringent and complete response all the way to progressive or refractory disease.”  — Dr. Kirollos Hanna  

While stop-loss insurance can be a complex and sometimes confusing topic, it enables employers to wrest control of rising employee health benefit costs. But when placing such coverage for a self-funded plan, it’s critically important to read the fine print and look beyond spreadsheet premiums for a high quality product. Without a concept called plan mirroring, carriers will audit to their stop-loss contracts, resulting in potential coverage gaps, according to Marla Kolbeck, director of stop-loss relationship, customer solutions at UMR, Inc. She explains that this approach closes any loopholes by ensuring that a stop-loss contract works hand in glove with the medical plan document to eliminate any surprises. Two types of stop-loss coverage are specific coverage involving a single claimant and aggregate coverage, which protects against the accumulation of many claims exceeding an agreed upon level. An additional level of protection includes aggregating a specific coverage deductible. With so many managing general underwriters (MGUs) and stop-loss carriers to choose from, Kolbeck says there are notable offerings that differentiate service providers. One such example is advanced funding, which protects employers from unplanned cash flow fluctuation by holding the plan sponsor’s provider payments for medical claims processed for individuals whose covered claims exceed the specific stop-loss deductible. Another is an experience refund, which is the portion of an insurance company’s premiums or profits to be returned to the policyholder if loss experience is better than expected.  Press play to learn more about the nuances of stop-loss insurance.

Stacie is a living proof of a positive and discipline mindset and what we can do for our own healing. Even though Stacie was a health coach before cancer and lived a healthy life, she was diagnosed with a rare disorder called MGUS (Monoclonal gammopathy of undetermined significance - precursor of Multiple Myeloma). And a year later, she received a bone cancer diagnosis. Stacie's story is a confirmation that "Food is Thy Medicine" and that if we are prepared to do whatever it takes to live, we can not only survive but truly thrive.

Kanama bozukluğu ile acil servise başvuran hastaların yönetimini konu alan 2 makaleden derlediğim yazıyı sizlerle paylaşıyorum​1,2​. İyi okumalar... Acil serviste kanamanın tetkik ve yönetiminde hekimleri endişelendiren noktalar şunlardır. Yaygın veya nadir etiyolojilerin uzun listesi ve kanama nedeninin doğru teşhisi Uygun tetkikler ve sonuçların yorumlanmasıUzuv veya hayatı tehdit eden komplikasyonları önlemek için kanama semptomlarının zamanında yönetimi Bir kanama hastasının yönetimi için en önemli nokta öyküdür: Kanama semptomlarıAldığı tedaviler/ilaçlar(antikoagülanlar, antitrombositler), Travma/yaralanma mekanizmasıKendisi veya ailesinde teşhis edilmiş kanama bozuklukları veya semptomlarıAcil tanınması gereken kanamanın netliği ve şiddeti Fizik muayenede, mukokutanöz, derin doku veya eklem kanaması belirtilerine odaklanmalı ve bilinen kanama diyatezi olan hastalarda kanama semptomlarına katkıda bulunabilecek yapısal lezyonlar değerlendirilmelidir. Kanama bozukluğu tanısı olmayan erişkin kanamalı hastada anormal pıhtılaşma testlerine yaklaşım Olgu 1: Prostat kanseri tanılı aspirin kullanan, paroksismal atriyal fibrilasyon öyküsü olan 76 yaşında erkek, birkaç günlük hematüri, sağ baldır ağrısı, şişlik ve morarma ile acil servise başvuruyor. İlk değerlendirmede derin ven trombozu düşünülüyor. Doppler USG tromboz yok, popliteal fossada 16×3.6×4 cm kompleks kist saptanmış. Radyolojik izlenim komplike Baker’ın kisti. Başlangıç kan tetkikleri normal, önerilerle taburcu edilmiş. Hasta dört gün sonra artan baldır ağrısı ve presenkop semptomlarıyla acil servise yeniden başvuruyor. Tabloda tetkik sonuçları mevcut ve aPTT giderek uzamış. Kist ultrasonografi eşliğinde aspire edilmiş taze kan görülmüş. BT görüntülemesinde gastroknemius hematomunda genişleme saptanmış. Olgu 1 laboratuvar 4 yıl önce İlk başvuru İkinci başvuru Aspirasyon esnasında Hemoglobin (gr/dl) 15.4 9.2 6.8(ERT tx) 8.5 Platelet (109/l) - 434 - - INR 0.9 1.1 1.2 1.2 apTT(sn) 28.1 79.1 96.5 103.2 Hematoloji takibi, fibrinojen, von Willebrand faktör, faktör IX, X, XI ve XII normal.  Faktör VIII aktivitesi

What innovation is coming in 2020 in myeloma research? Dr. Robert Orlowski of the the MD Anderson Cancer Center shares the insights learned from the recent American Society of Hematology meeting and highlights leading edge research expected in 2020. There is a stunning amount of development happening in myeloma - immunotherapies like CAR T, bi-specific antibodies, tri-specific antibodies and antibody drug conjugates, new findings in precursor conditions like MGUS and smoldering myeloma, new targeted therapies for relapsed and refractory myeloma and a host of different treatment combinations. Dr. Orlowski will give a broad and comprehensive review of what we can expect to see in 2020. Join us for this favorite annual show.   Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and has received a SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thank you to our episode sponsor, GSK. 

Lisa and Sara talk to Consultant Haematologist Dr Chris Gregory about Immunoglobulins. The subject is approached from the point of view of primary care clinicians ordering immunoglobulin blood tests. We get Dr Gregory's opinion on when it is useful to order an immunoglobulins blood test and go through the possible meaning of all the different types of results. We discuss raised immunoglobulin tests and the difference between monoclonal and polyclonal rises. We discuss the diagnosis of MGUS (monoclonal gammopathy of undetermined significance) and myeloma.   ____ Have feedback or suggestions? You can help us know how we are doing with our 3 minute survey: https://www.surveymonkey.co.uk/r/YYQ763C  ____ This podcast has been made with the support of Wigan CCG. Given that they are recorded with Wigan clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it’s release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Irene Ghobrial, MD of the Dana Farber Cancer Institute and Ivan Borrello, MD of Johns Hopkins are leading the largest study on precursor myeloma conditions that will include 50,000 patients and family members. The goal of the study is to detect myeloma early and see why and how patients who have MGUS and smoldering myeloma progress to active myeloma. The study is also seeking to understand the genetic, molecular and immune factors that lead to disease progression with the hope that this knowledge could stop disease progression and improve survival with effective strategies.   If you are African American or family member of a myeloma patient between the ages of 40-75, it's time to join this important study, which requires no travel. These two groups are involved in the study because they are more likely to develop into active myeloma. The Dream Team will study this group in an effort to define biological characteristics that will help to identify which patients will benefit from particular therapies. These biological characteristics include inherited mutations, acquired mutations, and immune factors. The Dream Team will also identify lifestyle and demographic factors that contribute to disease progression, such as obesity and race. The PROMISE study is funded by Stand Up To Cancer, who has provided a $10 million award to the Myeloma Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma through detection of early conditions before they turn into full-blown disease.  Learn more about how you and your family members can join! Thanks to our episode sponsor, Karyopharm Therapeutics  

In this episode I cover myeloma.If you want to follow along with written notes on myeloma go to zerotofinals.com/medicine/haematology/myeloma/ or the haematology section in the Zero to Finals medicine book.This episode covers the definitions, pathophysiology, tests, risk factors and treatments of myeloma. The audio in the episode was expertly edited by Harry Watchman.

To finish off Multiple Myeloma Awareness Month, we have our second episode of a two part series- this one's on Myeloma! We discuss the definitions of smoldering myeloma vs. multiple myeloma as well as a breakdown of the pathophysiology (with our mnemonic CRAB) and a brief overview of treatment. Make sure to listen to our episode on MGUS first. As always, we have an associated infographic as well as relevant resources at www.theinternatwork.com.This episode was written by Dr. Zahra Merali (Internal Medicine Resident) and reviewed by Dr. Laura Habib (Malignant Hematology Fellow), Dr. Mohammed Aljama (Malignant Hematologist) and Dr. Rajendar Hanmiah (General Internist). Infographic by Nikhita Singhal. 

It's Myeloma Awareness Month, and to spread the word we are releasing 2 concurrent episodes- MGUS and Myeloma. This week you are in the outpatient GIM clinic and our episode is all about Monoclonal Gammopathy of Undetermined Significance.  We delve deeper into what it means to order SPEP, UPEP, serum immunofixation and serum free light chains, and we overview the International Myeloma Working Group definitions of MGUS. As always, we have an associated infographic as well as relevant resources at www.theinternatwork.com.This episode was written by Dr. Zahra Merali (Internal Medicine Resident) and reviewed by Dr. Laura Habib (Malignant Hematology Fellow), Dr. Mohammed Aljama (Malignant Hematologist) and Dr. Rajendar Hanmiah (General Internist). Infographic by Nikhita Singhal. 

Welcome to the ninth episode of "What we have learnt this week…..”. These are short, 15minute, podcasts where we discuss topics that we have encountered the preceding week; whether it be on the wards, in a journal, at teaching or even on twitter! This week Chris, Emma and Vicky are recording during lunch at their regional geriatrics teaching day. They will be discussing myeloma and MGUS; attendance and carers allowance and dual anti platelet therapy in minor stroke and high risk TIAs.   Useful links this week are: https://www.gov.uk/attendance-allowance https://www.gov.uk/carers-allowance https://b-s-h.org.uk/guidelines/guidelines/investigation-of-newly-detected-m-proteins-and-the-management-of-mgus/ https://www.stroke.nih.gov/documents/NIH_Stroke_Scale_508C.pdf https://www.bmj.com/content/363/bmj.k5130/rr-0        

If you enjoyed this podcast, make sure to subscribe for more weekly education content from ASCO University. We truly value your feedback and suggestions, so please take a minute to leave a review. If you are an oncology professional and interested in contributing to the ASCO University Weekly Podcast, email ascou@asco.org for more information. TRANSCRIPT Welcome to the Self-Evaluation episode of the ASCO University weekly podcast. My name is Dr. Karen Winkfield, and I am Associate Director for Cancer Health Equity and Director of Hematologic Radiation Oncology at the Comprehensive Cancer Center at Wake Forest Baptist Health in Winston-Salem North Carolina. Today, we feature a self-evaluation question on the treatment of multiple myeloma and other plasma cell dyscrasias, and we begin by reading the question stem. A 65-year-old woman was found to have free light-chains in her urine after she presented with proteinuria. A 24-hour urine collection contained 0.6 grams of monoclonal lambda light-chains, and the urinary sediment was normal. She had normal complete blood count, renal function, and serum lactate dehydrogenase and calcium levels. Serum protein electrophoresis was normal with no monoclonal component. Subsequent free light-chain, or FLC, studies revealed kappa at 68.5 milligram per liter and lambda at 16.7 milligram per liter with FLC ratio of 4.1 with a normal range of 0.26 to 1.65. The bone marrow aspirate revealed 6% of mature-looking plasma cells. Bone marrow biopsies failed to demonstrate any amyloid deposits. Both conventional and fluorescent in situ hybridization cytogenetic analyses were normal. Skeletal X-rays, as well as spinal access MRIs were normal. The diagnosis is light-chain monoclonal gammopathy of undetermined significance, or LC MGUS. Which of the following is an accurate description of this disease? A, around 30% of cases present with kidney disease. B, around 3/10 of 1% per year of cases progress to light-chain multiple myeloma. C, around 30% of all MGUS is comprised of this condition. D, around 3% of the general population older than 50 years has this condition. [MUSIC PLAYING] The correct answer to this question is B, around 3/10 of 1% per year of cases progress to light-chain multiple myeloma. This answer reflects the natural history of LC MGUS. Briefly, the other choices presented in this question are incorrect for the following reasons. Approximately 23% of LC MGUS cases have or will develop renal disease. Therefore, answer A slightly overstates the incidence at 30%. Similarly, LC MGUS comprises only 19% of total cases of MGUS. This is consistent with the proportion of light-chain multiple myeloma cases among newly-diagnosed multiple myeloma patients. An estimated 0.8% of the general population age 50 years and older has LC MGUS. Thank you for listening to this week's episode of the ASCO University weekly podcast. For more information on the treatment of multiple myeloma and other plasma cell dyscrasias, visit the comprehensive E-Learning Center at university.asco.org. [MUSIC PLAYING] The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Stand Up To Cancer has announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease.  The team will be led by Irene Ghobrial, MD at Dana-Farber Cancer Institute (DFCI) in Boston and Ivan M. Borrello, MD, of Johns Hopkins University School of Medicine.  The hypothesis of this proposal is that early detection of MGUS/SMM in a high-risk population, along with a good understanding of the molecular and immune factors that lead to disease progression, will lead to effective strategies that intercept disease progression and improve survival. The Dream Team proposes to conduct a screening study of individuals over the age of 45, who are at a high risk for having MGUS or SMM, such as African-Americans and individuals who have a first-degree relative that has been diagnosed with a plasma cell disorder. This study will be called the PROMISE study. We will focus on these populations because they are two to three-fold more likely than others to have these precursor conditions. The Team expects to screen 50,000 individuals to obtain 3,000 MGUS/smoldering myeloma cases to intensively study and follow over time. The Dream Team will study this group in an effort to define biological characteristics that will help to identify which patients will benefit from particular therapies. These biological characteristics include inherited mutations, acquired mutations, and immune factors. The Dream Team will also identify lifestyle and demographic factors that contribute to disease progression, such as obesity and race. The Dream Team will use this information to develop new therapeutics that that can be used to prevent myeloma from progressing.     

In the latest of our Four Questions For series; Scott Steinmetz, Global Head of MidCorp within Allianz Risk Consulting (ARC) answers questions around the role of ARC in the program industry and how MGUs are supported. Get a quick overview of program performance and learn how technology is playing a pivotal role for Program Administrators. Don't forget to follow us on Twitter: @AGCS_Insurance Rate, review and subscribe to the podcast on iTunes: bit.ly/AGCSpodcast To learn more about AGCS, visit our website! www.AGCS.Allianz.com

Multiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to myeloma patients in this informative. show.  Diahanna is Owner and Founder of Critical Care Financial Consulting, LLC which takes a holistic approach to managing your finances in the face of a critical or chronic illness. She is an 18+ year Financial Advisor, providing Holistic planning for individuals and businesses and has 9+ years as a project Manager in Healthcare Services, Construction and the Investment Industries. Diahanna has a BA in Political Science and is HIPPA Certified. She also received her training as an Oncology Financial Patient Advocate from George Washington University. Diahanna is Licensed as a Health and Life Agent and is also maintains her Series 7 Investment Brokers License as well as the 63, and 66. Until recently, Diahanna was the Board President of The Leukemia and Lymphoma Society of KY and Southern Indiana. From 2015 until July 2017. Diahanna became intimately interested in financial planning for the critically and chronically ill after her husband was diagnosed with MGUS in 2002 then myeloma in 2005. Diahanna lives in Louisville, Kentucky and has two sons and 1 granddaughter. Thanks to our episode sponsor, Takeda Oncology.

Attorney Robert Tomilson is a partner at Clark Hill, an insurance law practice based in Philadelphia, PA. He serves as an insurance subject matter expert in the areas of insurers, reinsurers, and intermediaries in litigation and regulatory investigations. He also serves as an advisor to the American Law Institute’s Restatement of the Law of Liability Insurance as well as an adjunct professor of insurance at Drexel University School of Law. Robert joins me today to discuss the differences between MGAs and MGUs, the various challenges associated with each, and the risk factors to consider when starting a new innovative insurance agency. He also shares tips on how new insurance agencies can leverage regulations to speed the process of starting their organization. “The regulations are not always transparent for how to comply.” - Robert Tomilson Today on Spot On Insurance: What are MGUs and MGAs How MGUs differ from MGAs Challenges of getting set up as an insurance provider in multiple states The risks of innovation in the insurance industry The importance of understanding what the laws and regulations require Why it may be better to get licensed in a different jurisdiction Ways to use the regulations in your favor as a startup insurance agency  Key Takeaways: Be aware that the insurance industry tends to operate slowly and cautiously. Hire knowledgeable staff. Have the judgement and experience to make good use of the regulations.  Connect with Robert Tomilson: www.clarkhill.com   This episode was brought to you by… Spot On Insurance is brought to you by Insurance Licensing Services of America (ILSA), America’s Premier Insurance Licensing experts. To learn more about ILSA and their services, visit ILSAinc.com. Connect, Learn, Share Thank you for joining us on this week’s episode of Spot On Insurance. For more resources and episodes, visit SpotOnInsurance.com. Subscribe so you never miss an episode. Love what you’re learning, Spot Light your review on iTunes and share your favorite episodes with friends and colleagues!  

Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely to progress and is thus most likely to receive treatment. Dr. Manasanch is also studying the new monoclonal antibody Isatuximab in a clinical trial for high-risk smoldering myeloma patients. The road to a cure may be earlier treatment in these precursor conditions while the disease is not as complex or aggressive. Learn more about this fascinating work to prevent myeloma from happening in the first place.

For over sixty years Dr. Robert Kyle, MD of the Mayo Clinic led the way in myeloma research and was the pioneer that defined and determined early precursor conditions MGUS and smoldering myeloma in the late 1970s and early 1980s.  He joins us to share over 40 years of data from an extensive longitudinal study and his key findings on these precursor conditions of multiple myeloma. Dr. Kyle's groundbreaking work has changed how smoldering myeloma is diagnosed and treated. Learn what deep expertise can tell us about myeloma progression from these early stages and what it means for you. Special thanks to our episode sponsor, Takeda Oncology

Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene Ghobrial, MD wonders why we are waiting until progression to treat when we have newer non-toxic therapies to use. Dr. Ghobrial shares her Prevention of Progression Clinic's efforts to keep myeloma at bay. In this show, she shares her open study (observational) that includes all MGUS and smoldering myeloma patients. It's easy to join - just mail her blood and marrow samples when you have your regular testing done and they will keep track of how progression happens and why. 

Join the Common Rounds as we go into detail about what goes wrong when plasma cells produce large amounts of antibodies. Learn about Multiple Myeloma and it’s clinical features CRABs. Find out what MGUS means

Hear from Dr. Brendan Weiss, MD from the Abramson Cancer Center at the University of Pennsylvania about the indicators and factors that can MGUS progression to myeloma and a host of immunotherapy approaches that are up-and-coming both in the lab and clinic. He will also share his work on the bone marrow environment, how obesity impacts transplant, and how MGUS in racial groups.

Hear from Dr. Brendan Weiss, MD from the Abramson Cancer Center at the University of Pennsylvania about the indicators and factors that can MGUS progression to myeloma and a host of immunotherapy approaches that are up-and-coming both in the lab and clinic. He will also share his work on the bone marrow environment, how obesity impacts transplant, and how MGUS in racial groups.

Listen to Dr. Shaji Kumar, MD of the Mayo Clinic in Rochester as he describes how all myeloma was once MGUS, how new inhibitors (like CDK and HDAC) work, and his study of how cytogenetics impacts disease progression. 

Listen to Dr. Shaji Kumar, MD of the Mayo Clinic in Rochester as he describes how all myeloma was once MGUS, how new inhibitors (like CDK and HDAC) work, and his study of how cytogenetics impacts disease progression. 

This week on HealthTree Podcast for Multiple Myeloma, listen to Dr. Robert A. Kyle, a pioneer in myeloma research, as he gives us perspective on the history of "Innovation in Myeloma" and his lengthy research as the first to identify MGUS and smoldering myeloma. 

This week on mPatient Myeloma Radio, listen to Dr. Robert A. Kyle, a pioneer in myeloma research, as he gives us perspective on the history of "Innovation in Myeloma" and his lengthy research as the first to identify MGUS and smoldering myeloma. 

This week on HealthTree Podcast for Multiple Myeloma, listen to Dr. Landgren as we discuss his research in new therapies for myeloma in its precursor states (MGUS and smoldering), molecular profiling of myeloma and why it is important in predicting progression, and his related research with myeloma and the immune system. 

This week on mPatient Myeloma Radio, listen to Dr. Landgren as we discuss his research in new therapies for myeloma in its precursor states (MGUS and smoldering), molecular profiling of myeloma and why it is important in predicting progression, and his related research with myeloma and the immune system. 

The use of novel agents bortezomib, lenalidomide and thalidomide in Asian patients is discussed. Bortezomib is used as induction therapy and lenalidomide and thalidomide are reserved for relapsed or refractory patients in Japan. Rare reports of complications with these agents have been reported, However these are not believed to be treatment related. The increased incidence of cancer in survivors of the atomic bomb during World War II has been addressed at IMW. Results from the Life Span Study investigating radiation effects on leukaemia, lymphoma and MM incidence in atomic bomb survivors were presented at this year's IMW meeting. This study found that the radiation exposure associated with this may be a possible predisposing factor for MGUS. However, the incidence of multiple myeloma appears to be the same as Western populations. Overall, the incidence of MM appears to be lower in the Asian population, but higher rates have been noted in Vietnamese patients. A number of clinical studies are ongoing covering the use of novel therapies, autologous stem cell transplant and maintenance therapy.

This expert panel discussion filmed at the 14th International Myeloma Workshop, 3-7th April, looks at understanding of new data in the diagnosis and prognosis of multiple myeloma. Pomalidomide and carfilzomib have recently been approved in the US for treatment of multiple myeloma (MM). Pomalidomide was approved on the basis of two Phase II trials. A robust response of approximately 30% was seen in both studies in double refractory patients, with durability of response and impressive progression free survival (PFS) and overall survival (OS). In both trials, a predictable and manageable toxicity profile was observed. This drug represents a significant advance in the treatment of MM. Combination studies (with bortezomib and carfilzomib) and subgroup studies are underway. Carfilzomib received accelerated approval last year with low dose dexamethasone as a premedication and now in combination. It has shown clear activity in the context of double refractory relapse disease. Carfilzomib is associated with relatively low rates of neurotoxicity. There are other toxicities, although these are believed to be generally manageable. The oral proteasome inhibitor, MLN9708, has shown favourable tolerability. Its activity in combination also appears to be encouraging. However, it does not seem to be as potent as IV or SC bortezomib. Treatment of high risk smouldering myeloma is a key topic at this year's IMW. Smouldering myeloma is a very heterogeneous group of patients, as it also includes MGUS patients who have a very low rate of progression to MM. At the other end of the spectrum are the high risk patients for progression, sometime referred to as 'early myeloma', most of whom will progress to full-blown MM in 2-3 years. Recent Spanish data has shown that thalidomide and dexamethasone in combination can delay the progression to MM, and improve the OS in this group of patients. Myeloma is not only a heterogeneous disease between individual patients, but also within an individual patient. There is more than one subtype of malignant cell, which has important implications for treatment. At any one time during the disease, a single subtype of clone can be dominant. This has been termed the 'clonal tide' in MM. Because of the changing face of MM over the course of the disease, it is thought that a patient showing initial resistance to a therapy who then relapses can subsequently show sensitivity to this treatment again, as the clonal pattern of their disease changes. It is now possible to track the presence of clones over time and it may be possible to develop a myeloma tool based on next generation sequencing to use in biopsies to monitor the clonal content and intervene early before the clone has become too complex. Several monoclonal antibodies have been investigated in MM in combination with lenalidomide and dexamethasone. Further studies are underway. The assessment of minimal residual disease (MRD) should be assessed both inside the bone marrow and outside the bone marrow. Outside the bone marrow, imaging techniques such as PET scan should become the gold standard. In the bone marrow, there are two imaging techniques available. The first of these is molecular imaging and the second is multiparameter flow cytometry (MFC). The latter is more applicable for use in routine laboratories. A combination of both extramedullary and intramedullary assessments would provide the best tool to help decide on therapy in the future. Currently, studies have shown that a positive MRD can help guide consolidation and maintenance therapy. Bisphosphonates are used routinely in MM patients. A recent study on zoledronic acid has shown that the use of zoledronic acid not only reduced bone disease but improved survival in the patients treated. This is the first time a survival advantage has been seen with supportive care. As a result, guidelines now recom

Dr Essex talks to ecancetv at the 14th International Myleoma Workshop, Kyoto, Japan, 3-7th April 2013. Multiple myeloma (MM) plasma cells co-cultured with stroma taken from MM bone marrow demonstrates that it is the stroma, rather than the plasma cell, that acts as a major determinant of disease progression in MM. The role of bone marrow mesenchymal stem cells (BMMSC) in the progression of MM and monoclonal gammopathy of undetermined significance (MGUS) was investigated. BMMSC were isolated from control, MGUS and MM bone marrow. The full genetic profile of these cells was examined using microarrays, with detailed pathway analysis to determine the genes involved in disease progression. 30 patients BMMSC were analysed using U133 plus 2.0 GeneChip microarrays; this highlighted 187 genes that had over a 1.5 fold difference in expression between control and disease BMMSC. Pathway analysis of these genes generated several differentially expressed pathways, with Wnt signalling being the most evident. Two Wnt pathway genes whose expression is significantly decreased in disease BMMSC are secreted frizzled-related proteins (sFRPs) 2 and 4. This decrease in expression was confirmed by RT-PCR, with a concurrent increase in methylation status suggesting these genes have become epigenetically silenced. Splice variant analysis of these particular genes showed a differential expression of exons, which may be functionally significant for Wnt signalling. For the first time Dr Essex's team showed profound silencing of negative regulators of Wnt signalling within MM and MGUS BMMSC, which may help to design early interventions aimed at patients in the premalignant state.

ASHRLD11 - A 75-year-old man with a history of MGUS and chronic bronchiectasis is diagnosed with MM with a t(11;14) translocation. Case discussion moderated by Neil Love, MD. Produced by Research To Practice.

The occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS). However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM). Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors, we detected SOX2-specific autoantibodies in 7.7% and 2.0% of patients and donors, respectively. We identified SOX2211-230 as an immunodominant antibody-epitope within the full protein sequence. SOX2 antigen was expressed in most healthy tissues and its expression did not correlate with the number of BM-resident plasma cells. Accordingly, anti-SOX2 immunity was not related to SOX2 expression levels or tumor burden in the patients' BM. The only clinical factor predicting the development of anti-SOX2 immunity was application of allogeneic stem cell transplantation (alloSCT). Anti-SOX2 antibodies occurred more frequently in patients who had received alloSCT (n = 74). Moreover, most SOX2-seropositive patients had only developed antibodies after alloSCT. This finding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen. The questions whether SOX2-specific autoantibodies merely represent an epiphenomenon, are related to graft-versus-host effects or participate in the immune control of myeloma needs to be answered in prospective studies.

SPEP vs. UPEP? What does it tell you and not tell you? What is the role for immunofixation and free light chains in diagnosis? Learn about paraneoplastic antibodies with MGCS and its renal, neurologic, and dermatologic manifestations!Sponsor: Freed is an AI scribe that listens and writes your note in < 30 seconds. Freed learns your style over time and is HIPAA compliant! Use the code CORE50 to get 50% off your first month with FreedBehind The Scenes Youtube Interview with Dr. Vincent Rajkumar Transcript and Show NotesTimestamps:(01:26) | Pearl 1: What is a monoclonal gammopathy? What is our expected clinical presentation?(10:12) | Pearl 2: What is our initial workup? Understanding SPEP, Immunofixation, and Free Light Chains(24:13) | Pearl 3: Do we need urine testing? When urine testing is necessary and when it is not.(26:26) | Pearl 4: How should we differentiate monoclonal gammopathies? The continuum of MGUS, SMM, and MM.(41:35) | Pearl 5: Demystifying Monoclonal gammopathy of clinical significance (MGCS)Tags: CoreIM, Internal Medicine, ClinicalPearls, Medical Education, IMCore, hospitalist, physician assistant, nurse practitioner, medical student, internal medicineFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy